Preclinical in vivo data demonstrate hyper-precise mechanism directly targets the disease-causing mRNA repeats leading to correction of splicing ...

Every science-fiction story needs an iconic setting. Frank Herbert’s Dune saga has no shortage of them, the most notable being the desert planet of Arrakis. Even if you’ve never read or seen Dune, ...

Denis Villeneuve's pair of Dune movies (which are streaming with a Max subscription) are already being considered some of the best sci-fi movies of all time. The pair of films is wildly popular, and ...

And, in short, that answer is… Yes. According to an article written in The Conversation, “much of Arrakis itself would indeed be habitable, albeit inhospitable.” Here’s how the scientists arrived at ...

In Dune, the Fremen people of Arrakis practice an odd future hybrid religion called “zensunni.” This adds an extra layer of ...

"Arrakis is Dune, and Dune is sand," said Dune: Awakening executive producer Scott Junior, describing the desert planet that serves as the setting for the upcoming multiplayer survival game. This ...

Director Denis Villeneuve will bid farewell to the franchise after Dune: Messiah is released. Although the filmmaker believes ...

Funcom has released an all-new video for Dune: Awakening this week, as they showed off all of the "beauty" of Arrakis. This is about three minutes worth of the team highlighting all of the work that ...

Funcom released a new trailer this week for Dune: Awakening, as they show off more of the world of Arrakis. The look of the planet is stunning and unforgiving, but it's more than just deserts, ...

Biotech veteran Michael Gilman “failed at retirement.” He sold his company Padlock Therapeutics to Bristol-Myers Squibb in early 2016 and contemplated calling it quits. Yet he found himself on the ...

A company developing small-molecule drugs that target RNA will receive nearly $200 million from Roche under a new partnership between the two. “We are excited to partner with Roche’s strong research ...

Arrakis Therapeutics raised $38 million in a Series A fundraising and named Michael Gilman, Ph.D., as its chairman and CEO. The financing round was led by Canaan Partners, with participation by Advent ...